Jasmine Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jasmine Li has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
Adem Saglam
1 shared publicationAiping Wu
1 shared publication- Alex J. Fulcher
Monash Micro Imaging, Monash University, Clayton, Australia
1 shared publication - Ana Maria Valencia-Hernandez
Australian Institute of Tropical Health and Medicine, James Cook University, Cairns and Townsville, Queensland, Australia
1 shared publication - Angela Nguyen
Department of Biochemistry and Molecular Biology, Immunity Program, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia
1 shared publication - Anita Quintal Gomes
Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal
1 shared publication
Latest Publications
- 1 December 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (23) , 5803-5805
Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis
Cancer immunotherapy utilizing checkpoint blockade antibodies or adoptive cellular therapy (ACT) with tumor-specific T cells has led to unprecedented clinical responses in patients with cancer and has been considered one of the most significant breakthroughs in cancer treatment in the past decade. Nevertheless, many cancers remain refractory to these therapies due to the presence of an immunosuppressive tumor microenvironment. This has led to the innovative idea of combining ACT with checkpoint inhibition. A landmark 2004 study by Blank and colleagues published in Cancer Research was one of the original demonstrations that adoptive transfer of T cells lacking the negative T-cell regulator, PD-1, was able to restore functional T-cell antitumor activity, resulting in rapid regression of established tumors in a preclinical model. This work was instrumental in not only driving clinical studies utilizing checkpoint inhibition but also a new wave of recent trials involving checkpoint blockade in the setting of ACT. See related article by Blank and colleagues, Cancer Res 2004;64:1140–5
- 1 December 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (23) , 5803-5805
Augmenting Adoptive T-cell Immunotherapy by Targeting the PD-1/PD-L1 Axis
Cancer immunotherapy utilizing checkpoint blockade antibodies or adoptive cellular therapy (ACT) with tumor-specific T cells has led to unprecedented clinical responses in patients with cancer and has been considered one of the most significant breakthroughs in cancer treatment in the past decade. Nevertheless, many cancers remain refractory to these therapies due to the presence of an immunosuppressive tumor microenvironment. This has led to the innovative idea of combining ACT with checkpoint inhibition. A landmark 2004 study by Blank and colleagues published in Cancer Research was one of the original demonstrations that adoptive transfer of T cells lacking the negative T-cell regulator, PD-1, was able to restore functional T-cell antitumor activity, resulting in rapid regression of established tumors in a preclinical model. This work was instrumental in not only driving clinical studies utilizing checkpoint inhibition but also a new wave of recent trials involving checkpoint blockade in the setting of ACT. See related article by Blank and colleagues, Cancer Res 2004;64:1140–5
- 4 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 372 (6546) , 1056-+
Canonical T cell receptor docking on peptide–MHC is essential for T cell signaling
Making sense of TCR–pMHC topology: Most T cells use a T cell receptor (TCR) that recognizes major histocompatibility complex molecules bound to peptides (pMHCs) derived from both self- and foreign antigens. Although there is great variability in the interface because of the diversity of both partners, this interaction displays a canonical docking topology for reasons that remain contested. Zareie et al. tested an assortment of both canonical and reversed-polarity TCRs that were all specific for the same cognate pMHC-I bearing a peptide derived from influenza A virus (IAV) (see the Perspective by Horkova and Stepanek). The authors determined that docking topology was the primary driver of in vivo T cell activation and recruitment when mice were infected with IAV. The canonical topology was required for the formation of a functional signaling complex, suggesting that T cell signaling constraints dictate how TCR and pMHC meet. Science , abe9124, this issue p. eabe9124 ; see also abj2937, p. 1038
- 4 June 2021
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 372 (6546) , 1056-+
Canonical T cell receptor docking on peptide–MHC is essential for T cell signaling
Making sense of TCR–pMHC topology: Most T cells use a T cell receptor (TCR) that recognizes major histocompatibility complex molecules bound to peptides (pMHCs) derived from both self- and foreign antigens. Although there is great variability in the interface because of the diversity of both partners, this interaction displays a canonical docking topology for reasons that remain contested. Zareie et al. tested an assortment of both canonical and reversed-polarity TCRs that were all specific for the same cognate pMHC-I bearing a peptide derived from influenza A virus (IAV) (see the Perspective by Horkova and Stepanek). The authors determined that docking topology was the primary driver of in vivo T cell activation and recruitment when mice were infected with IAV. The canonical topology was required for the formation of a functional signaling complex, suggesting that T cell signaling constraints dictate how TCR and pMHC meet. Science , abe9124, this issue p. eabe9124 ; see also abj2937, p. 1038
- 26 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (48)
Glycolipid-peptide vaccination induces liver-resident memory CD8 + T cells that protect against rodent malaria
Glycolipid-peptide conjugate vaccines protect against rodent malaria by generating large numbers of liver CD8 + T RM cells.
- 26 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 5 (48)
Glycolipid-peptide vaccination induces liver-resident memory CD8 + T cells that protect against rodent malaria
Glycolipid-peptide conjugate vaccines protect against rodent malaria by generating large numbers of liver CD8 + T RM cells.
- 1 January 2020
- Published by Elsevier
Contributors